Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
39 studies found for:    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Show Display Options
Rank Status Study
21 Not yet recruiting Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Procedure: Muscle Magnetic Resonance Imaging (RMI) evaluation;   Device: MRI
22 Completed MRI in Diagnosing and Monitoring CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention:
23 Completed Immunoglobulin Dosage and Administration Form in CIDP and MMN
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Multifocal Motor Neuropathy;   Hemolytic Anemia
Intervention: Drug: Immunoglobulins
24 Recruiting Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Biological: HYQVIA;   Biological: 0.25% albumin placebo solution with rHuPH20;   Biological: IGIV
25 Completed Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg
Condition: Demyelinating Polyneuropathy
Interventions: Drug: Immunoglobulin perfusion;   Drug: Prednisone
26 Recruiting Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E
27 Withdrawn Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
Condition: Chronic Inflammatory Demyelinating Polyneuropathy
Intervention: Drug: H.P. Acthar® Gel
28 Recruiting Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Intervention: Drug: I10E
29 Terminated Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP
Condition: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions: Drug: NewGam 10%;   Drug: Placebo
30 Completed Study of CIDP Patients During IVIG Treatment
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Drug: intravenous gammaglobulin
31 Not yet recruiting Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy
Condition: Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy
Intervention: Drug: NewGam
32 Completed Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Drug: Immune globulin
33 Recruiting Transcriptome Analysis of the Peripheral Blood in CIDP
Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy;   Autoimmune Diseases;   Clarkson Syndrome;   Muscular Autoimmune Disorders
Intervention: Drug: IVIg
34 Completed Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Intervention: Drug: immune globulin
35 Recruiting IVIg for Demyelination in Diabetes Mellitus
Conditions: Peripheral Neuropathy;   Diabetes Mellitus;   Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Drug: 10% intravenous immunoglobulin (IVIg);   Drug: 0.9% sodium chloride
36 Recruiting Stem Cell Transplantation for Stiff Person Syndrome (SPS)
Condition: Stiff Person Syndrome
Intervention: Biological: Autologous Hematopoietic Stem Cell Transplantation
37 Recruiting SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy;   Peripheral Neuropathy;   Charcot-Marie-Tooth Disease;   Charcot-Marie-Tooth Disease Type 1A;   Charcot-Marie-Tooth Disease, Type IA
Intervention: Drug: MD1003
38 Active, not recruiting Interest of Mycophenolate for CIDP Weaning
Condition: Chronic Inflammatory Demyelinating Polyradiculopathy
Interventions: Drug: Mycophenolate Mofetil;   Drug: placebo
39 Recruiting Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
Conditions: Diabetes Mellitus, Type 1;   Diabetes Mellitus, Type 2;   Diabetic Polyneuropathy;   Hereditary Axonal Neuropathy;   Hereditary Demyelinated Neuropathy;   Polyneuropathy, Inflammatory Demyelinating, Chronic
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-39) Next Page   
Study has passed its completion date and status has not been verified in more than two years.